Suppr超能文献

COVID-19 的流行病学、发病机制、临床特征、诊断和治疗:当前证据的综述。

Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence.

机构信息

School of Medicine, American University of Integrative Sciences (AUIS), Bridgetown, Barbados.

出版信息

Expert Rev Clin Pharmacol. 2021 May;14(5):601-621. doi: 10.1080/17512433.2021.1902303. Epub 2021 May 3.

Abstract

INTRODUCTION

The COVID-19 pandemic has created a public health crisis, infected millions of people, and caused a significant number of deaths. SARS-CoV-2 transmits from person to person through several routes, mainly via respiratory droplets, which makes it difficult to contain its spread into the community. Here, we provide an overview of the epidemiology, pathogenesis, clinical presentation, diagnosis, and treatment of COVID-19.

AREAS COVERED

Direct person-to-person respiratory transmission has rapidly amplified the spread of coronavirus. In the absence of any clinically proven treatment options, the current clinical management of COVID-19 includes symptom management, infection prevention and control measures, optimized supportive care, and intensive care support in severe or critical illness. Developing an effective vaccine is now a leading research priority. Some vaccines have already been approved by the regulatory authorities for the prevention of COVID-19.

EXPERT OPINION

General prevention and protection measures regarding the containment and management of the second or third waves are necessary to minimize the risk of infection. Until now, four vaccines reported variable efficacies of between 62-95%, and two of them (Pfizer/BioNTech and Moderna) received FDA emergency use authorization. Equitable access and effective distribution of these vaccines in all countries will save millions of lives.

摘要

简介

COVID-19 大流行造成了公共卫生危机,感染了数百万人,并导致大量死亡。SARS-CoV-2 通过几种途径在人与人之间传播,主要通过呼吸道飞沫,这使得很难控制其在社区中的传播。在这里,我们提供了 COVID-19 的流行病学、发病机制、临床特征、诊断和治疗的概述。

涵盖领域

直接的人与人之间的呼吸道传播迅速扩大了冠状病毒的传播。在没有任何临床证实的治疗方法的情况下,目前 COVID-19 的临床管理包括症状管理、感染预防和控制措施、优化的支持性护理以及严重或危急疾病的重症监护支持。开发有效的疫苗现在是首要的研究重点。一些疫苗已经获得监管机构批准,可用于预防 COVID-19。

专家意见

为了最大限度地降低感染风险,需要针对遏制和管理第二波或第三波疫情采取一般预防和保护措施。到目前为止,报告的四种疫苗的有效性在 62%-95%之间,其中两种(辉瑞/生物技术和 Moderna)已获得 FDA 紧急使用授权。在所有国家公平地获得和有效分配这些疫苗将拯救数百万人的生命。

相似文献

1
Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence.
Expert Rev Clin Pharmacol. 2021 May;14(5):601-621. doi: 10.1080/17512433.2021.1902303. Epub 2021 May 3.
3
COVID-19: Characteristics and Therapeutics.
Cells. 2021 Jan 21;10(2):206. doi: 10.3390/cells10020206.
5
An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies.
Expert Rev Anti Infect Ther. 2021 Jul;19(7):877-888. doi: 10.1080/14787210.2021.1863146. Epub 2020 Dec 29.
6
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1.
9
Management of COVID-19: current status and future prospects.
Microbes Infect. 2021 May-Jun;23(4-5):104832. doi: 10.1016/j.micinf.2021.104832. Epub 2021 Apr 17.
10
COVID-19 vaccines: concerns beyond protective efficacy and safety.
Expert Rev Vaccines. 2021 Aug;20(8):1013-1025. doi: 10.1080/14760584.2021.1949293. Epub 2021 Jul 5.

引用本文的文献

3
Differentiation of the Cytokine Profile Modified by SARS-CoV-2 and Influenza Virus in an In Vitro Experiment.
Bull Exp Biol Med. 2025 May;179(1):54-57. doi: 10.1007/s10517-025-06430-x. Epub 2025 Jul 18.
5
Prognostic Accuracy of Nutritional Assessment Tools in Critically-Ill COVID-19 Patients.
J Clin Med. 2025 May 13;14(10):3382. doi: 10.3390/jcm14103382.
6
Clara cell 16 kDa protein: an important marker for COVID-19 severity.
Front Immunol. 2025 Apr 1;16:1527377. doi: 10.3389/fimmu.2025.1527377. eCollection 2025.
8
COVID-19 Infection, Vaccination, and Severe Coronary Artery Disease in Türkiye: A Retrospective Analysis.
Anatol J Cardiol. 2025 Mar 28;29(7):339-46. doi: 10.14744/AnatolJCardiol.2025.5105.
9
Late-Onset Urticarial and Erythema Multiforme-Like Eruption Following SARS-CoV-2 Infection.
Cureus. 2025 Feb 5;17(2):e78547. doi: 10.7759/cureus.78547. eCollection 2025 Feb.

本文引用的文献

4
Moderna COVID vaccine becomes second to get US authorization.
Nature. 2020 Dec 18. doi: 10.1038/d41586-020-03593-7.
5
Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity.
Cell. 2021 Jan 7;184(1):64-75.e11. doi: 10.1016/j.cell.2020.11.020. Epub 2020 Nov 19.
6
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
7
One year update on the COVID-19 pandemic: Where are we now?
Acta Trop. 2021 Feb;214:105778. doi: 10.1016/j.actatropica.2020.105778. Epub 2020 Nov 28.
8
Why Oxford's positive COVID vaccine results are puzzling scientists.
Nature. 2020 Dec;588(7836):16-18. doi: 10.1038/d41586-020-03326-w.
10
Nebulised interferon beta-1a for patients with COVID-19.
Lancet Respir Med. 2021 Feb;9(2):122-123. doi: 10.1016/S2213-2600(20)30523-3. Epub 2020 Nov 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验